Interference test kit components are available for individual sale or in customer-defined combinations, addressing the need of laboratories and manufacturers to simplify the evaluation of assays for common interferents.
Molecular diagnostics company Biodesix announced that it has closed $8.4 million in Series E financing. The capital will help develop the company's mass-spec technology platform and market the company's first test, VeriStat, to guide NSCLC therapy.
Richard Lee and John Swindle discuss how the SOMAscan proteomic assay tool supports their research in a free webinar offered by SomaLogic. Pharmacology and Pathology; SOMAscan Hunting will take place November 14.
Contact us about this feature or to become an expert.
CLP is the only magazine that focuses exclusively on products and technology for the clinical lab industry. Every month, CLP's editorial provides 45,000 pathologists, lab managers, administrators and technologists with comprehensive coverage of new products and technology.